Christopher J. Senner - Sep 21, 2021 Form 4 Insider Report for EXELIXIS, INC. (EXEL)

Role
EVP and CFO
Signature
/s/ Jennifer Drimmer Rokovich, Attorney in Fact
Stock symbol
EXEL
Transactions as of
Sep 21, 2021
Transactions value $
-$789,909
Form type
4
Date filed
9/23/2021, 08:16 PM
Previous filing
Jun 17, 2021
Next filing
Oct 4, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction EXEL Common Stock Options Exercise $329K +90K +25.24% $3.66* 447K Sep 21, 2021 Direct F1
transaction EXEL Common Stock Tax liability -$1.12M -55.1K -12.33% $20.33 392K Sep 21, 2021 Direct F2
holding EXEL Common Stock 2.72K Sep 21, 2021 By 401(k) F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EXEL Option (right to buy) Options Exercise $0 -90K -100% $0.00* 0 Sep 21, 2021 Common Stock 90K $3.66 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 208,343 shares of Exelixis, Inc. common stock ("Common Stock") that will be issued to the Reporting Person upon vesting of restricted stock units.
F2 Represents a "net exercise" of an outstanding stock option. The Reporting Person received 34,943 shares of Common Stock on the net exercise of a stock option to purchase 90,000 shares of Common Stock. The Issuer withheld 55,057 shares of Common Stock underlying the stock option for payment of the exercise price and tax withholding using a stock price on September 21, 2021 of $20.33.
F3 Represents shares of Common Stock under the Exelixis, Inc. common stock under the Exelixis, Inc. 401(k) Plan, pursuant to a plan statement dated as of September 22, 2021.
F4 The option, representing the right to purchase a total of 350,000 shares of Common Stock, became fully exercisable on July 15, 2019.